Retrospective evaluation of image-guided interventional treatments of venous and arteriovenous malformations of the face

Recruiting

Conditions: Q67.4
Q87.8
Other congenital deformities of skull, face and jaw
Other specified congenital malformation syndromes, not elsewhere classified

Registration Number: DRKS00026660

Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 20

Inclusion Criteria

Patients diagnosed with lymphatic, arteriovenous or venous malformation of the face and having undergone image-guided treatment by sclerotherapy or embolization in the form of one or more sessions in the period from 01/01/2017 to 12/30/2021.
- Patients who have received the above procedures with the following sclerotherapy/embolization agents: Polidocanol, (gelled) alcohol, EVOH-based liquid embolization agents (EVOH = ethylene vinyl alcohol copolymer), bleomycin, OK 432 (picibanil), doxycycline, STS (sodium tetradecyl sulfate).

Exclusion Criteria

- Patients with lymphatic, arteriovenous or venous malformation without facial involvement.
- Patients who have received other image-guided interventional procedures, e.g., electrosclerotherapy

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective evaluation of image-guided interventional treatments of venous and arteriovenous malformations of the face.

Secondary Outcome Measures

Name	Time	Method
- Analysis of technical success after image-guided, interventional treatment of lymphatic, arteriovenous and venous malformations of the face (successful performance of the procedures)<br>- Analysis of devascularization of malformations after image-guided interventional treatment of lymphatic, arteriovenous and venous malformations of the face (grading of devascularization based on pre- and post-interventional imaging)<br>- Analysis of complication rate after image-guided interventional treatment of lymphatic, arteriovenous, and venous malformations of the face (periinterventional and postinterventional complications < 30 days).